Table 3.
Diagnostic performance for synchronous multiple primary malignant neoplasms occurring at the same time (SMPMNS): 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) vs. conventional imaging.
| Case | Conventional imaging prior to PET/CT | 18F-FDG PET/CT | ||||
|---|---|---|---|---|---|---|
| Diagnosed | M and/or AI | MD or missed | Diagnosed | M and/or AI | MD or missed | |
| 1 | Missed, MD | Missed, MD | ||||
| 2 | M | MD | + | M | ||
| 3 | M, AI | MD | + | M, AI | ||
| 4 | M | MD | + | M | ||
| 5 | + | + | ||||
| 6 | MD | + | ||||
| 7 | M | MD | + | M | ||
| 8 | Missed | + | ||||
| 9 | M | Missed | + | M | ||
| 10 | Missed | M | Missed | |||
| 11 | Missed | Missed | ||||
| 12 | + | + | M* | |||
| 13 | + | + | ||||
| 14 | Missed | + | ||||
| 15 | M | Missed | + | M | ||
| 16 | Missed | + | ||||
| 17 | M | MD | M | MD | ||
| 18 | MD | + | ||||
| 19 | + | + | ||||
| 20 | + | + | ||||
| 21 | Missed | Missed | ||||
| 22 | Missed | + | ||||
| 23 | M | MD | + | M | ||
| 24 | AI | Missed | + | AI | ||
| 25 | Missed | + | ||||
| 26 | Missed | + | M* | |||
| 27 | M | MD | M | MD | ||
| 28 | M | Missed | + | M | ||
| 29 | AI | Missed | + | M*, AI | ||
| 30 | Missed | + | M* | |||
| 31 | Missed | M | MD | |||
| 32 | Missed | + | M | |||
| 33 | Missed | + | ||||
| 34 | Missed | MD | ||||
| 35 | M | Missed | + | M | ||
| 36 | Missed | + | M | |||
| 37 | Missed | Missed | ||||
The plus sign means diagnosed with SMPMNS. Patient-based consistency test of the diagnostic performance between PET/CT and conventional imaging for SMPMNS: κ = 0.096, p = 0.173; McNemar test, p = 0.000. Patient-based consistency test for revealing primary tumors (diagnosed + misdiagnosed) between PET/CT and conventional imaging: κ = 0.277, p = 0.000; McNemar test, p = 0.001.
M, metastasis; AI, adjacent invasion; MD, misdiagnosed one primary tumor as a metastasis; missed, missed one primary tumor; M*, exclude metastasis by follow-up.